Paper36947282
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials.
Llanos-Paez C and 5 others. J Pharmacokinet Pharmacodyn, 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials. Papers, record 36947282. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36947282
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials.
- PubMed
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pulmonary Disease, Chronic Obstructive | Major topic |
| Humans | |
| Forced Expiratory Volume |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27103795 | A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. | Int J Chron Obstruct Pulmon Dis | 2016 | https://conductscience.org/library/papers/27103795 | PubMed |
| 2 | 29668352 | Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29668352 | PubMed |
| 3 | 30993679 | Model-Based Meta-Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence. | Clin Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30993679 | PubMed |
| 4 | 27663386 | Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. | Respir Res | 2016 | https://conductscience.org/library/papers/27663386 | PubMed |
| 5 | 28480503 | Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis. | Clin Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28480503 | PubMed |
| 6 | 27730198 | A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD. | ERJ Open Res | 2016 | https://conductscience.org/library/papers/27730198 | PubMed |
| 7 | 21518459 | Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. | Respir Res | 2011 | https://conductscience.org/library/papers/21518459 | PubMed |
| 8 | 20843247 | Susceptibility to exacerbation in chronic obstructive pulmonary disease. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20843247 | PubMed |
| 9 | 21991892 | Changes in forced expiratory volume in 1 second over time in COPD. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21991892 | PubMed |
| 10 | 27884052 | Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. | CPT Pharmacometrics Syst Pharmacol | 2017 | https://conductscience.org/library/papers/27884052 | PubMed |
| 11 | 28993871 | Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies. | Lung | 2017 | https://conductscience.org/library/papers/28993871 | PubMed |
| 12 | 18836213 | A 4-year trial of tiotropium in chronic obstructive pulmonary disease. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18836213 | PubMed |
| 13 | 28375647 | FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. | Am J Respir Crit Care Med | 2017 | https://conductscience.org/library/papers/28375647 | PubMed |
| 14 | 35174432 | Applications of Model-Based Meta-Analysis in Drug Development. | Pharm Res | 2022 | https://conductscience.org/library/papers/35174432 | PubMed |
| 15 | 26517752 | Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis. | J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26517752 | PubMed |
| 16 | 27299940 | Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy. | CPT Pharmacometrics Syst Pharmacol | 2016 | https://conductscience.org/library/papers/27299940 | PubMed |
| 17 | 10195646 | Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. | Comput Methods Programs Biomed | 1999 | https://conductscience.org/library/papers/10195646 | PubMed |
| 18 | 23836189 | Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. | CPT Pharmacometrics Syst Pharmacol | 2013 | https://conductscience.org/library/papers/23836189 | PubMed |
| 19 | 30846476 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. | Eur Respir J | 2019 | https://conductscience.org/library/papers/30846476 | PubMed |
| 20 | 29094315 | Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. | Adv Ther | 2017 | https://conductscience.org/library/papers/29094315 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41023527 | Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach. | Dermatol Ther (Heidelb) | 2025 | https://conductscience.org/library/papers/41023527 | PubMed |
| 40536286 | A Combined Model-Based Meta-Analysis of Aggregated and Individual FEV1 Data From Randomized COPD Trials. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/40536286 | PubMed |
| 40442865 | Examining the Reliability of Model-Based Meta-Analysis (MBMA) Outcomes: A Simulation Study. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/40442865 | PubMed |
| 39164859 | Predicting progression-free survival from measurable residual disease in chronic lymphocytic leukemia. | Clin Transl Sci | 2024 | https://conductscience.org/library/papers/39164859 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CALML3 | 810 | PubTator's text mining | https://conductscience.org/library/genes/810 | NCBI Gene |
| MOK | 5891 | PubTator's text mining | https://conductscience.org/library/genes/5891 | NCBI Gene |
| NR5A1 | 2516 | PubTator's text mining | https://conductscience.org/library/genes/2516 | NCBI Gene |
| PDE4A | 5141 | PubTator's text mining | https://conductscience.org/library/genes/5141 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36947282
GET https://conductscience.org/api/papers/v1/36947282/references?page=2